Disclaimer

The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com. The DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe.

Press releases

Data from Roll-In Cohort of North American pivotal alfapump® study (POSEIDON) selected for poster presentation at AASLD The Liver Meeting®

  Presentation by Dr. Florence Wong on Sunday November 6th in Washington, DC: “An Automatic Low Flow Ascites Pump Improves Ascites Control and Quality of Life In Patients with Cirrhosis and Recurrent Ascites” Ghent, Belgium – 21 October 2022 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the...

Sequana Medical announces H1 2022 results and provides business update

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 8 September 2022, 07:00 CET   alfapump® – strong interim data / on track to report primary endpoint data of North American pivotal POSEIDON study in Q4 2022 DSR® – clinical evidence of disease-modifying heart failure drug therapy / preparations ongoing to start US phase 1b/2a MOJAVE study...

Sequana Medical Notice of 2022 Half Year Results and Business Update

Ghent, Belgium – 1 September 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, will announce its half year results ended 30 June 2022 on Thursday, 8 September 2022. The management team will host a...

Alexandra Clyde appointed to Sequana Medical Board of Directors

Seasoned medtech leader with more than 30 years’ healthcare experience Ghent, Belgium – 25 August 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces the appointment of Alexandra Clyde as an independent Non-Executive...

Sequana Medical secures EUR 10 million loan facility with Kreos Capital

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 20 July 2022, 07:00 CET   Company’s cash runway extended into Q3 2023 Ghent, Belgium – 20 July 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces...

Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 19 July 2022, 07:00 am CEsT   DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart...

Doug Kohrs appointed to Sequana Medical Board of Directors

Highly experienced US medtech leader brings more than 40 years’ experience Ghent, Belgium – 19 July 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces the appointment of Doug Kohrs as an independent Non-Executive...

Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders

PRESS RELEASE REGULATED INFORMATION 27 May 2022, 06:00 pm CEST   Ghent, Belgium – 27 May 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that all proposed resolutions submitted to the...

Sequana Medical announces Annual and Extraordinary General Meetings of Shareholders on 27 May 2022

PRESS RELEASE REGULATED INFORMATION 27 April 2022, 07:00 am CEST   Publication of Annual Report 2021 Ghent, Belgium – 27 April 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today invites the holders...

Sequana Medical announces 2021 Full Year Results and 2022 Outlook

PRESS RELEASE REGULATED INFORMATION 12 April 2022, 07:00 CET   alfapump® in liver disease Positive results from second interim analysis of POSEIDON pivotal study; encouraging survival data at 12 months vs. published literature Patient enrolment and implants completed; primary endpoint on track for Q4 2022 FDA regulatory submission planned for mid-2023 DSR® in heart failure...
1 2 3 4 5 14

Subscribe to our Press Releases

    PRESS RELEASES

    SUBSCRIBE TO OUR PRESS RELEASES